A rapid NT-proBNP cardiac biomarker test to manage HF

Used in conjunction with clinical assessment, the new Triage NT-proBNP (N-terminal pro b-type natriuretic peptide) test is a useful biomarker in the diagnosis and management of patients with heart failure (HF) its manufacturer Alere International reports.

‘BNP (b-type natriuretic peptide) and NT-proBNP levels can help doctors differentiate between HF and other problems, since the level of natriuretic peptides in the blood increases as chronic heart failure advances.’

In addition to a diagnosis in cases of suspected HF, the firm adds that the new test can also aid in assessing the risk of patients with heart failure, or acute coronary syndrome (ACS), or the increased risk for cardiovascular events and mortality in patients with stable coronary artery disease (CAD) who are also at risk of HF.
The Alere Triage NT-proBNP Test is CE marked for EU distribution.



Read all latest stories

Related articles


News • Cardiology insights

Lab-grown heart cells 'mimic' disease in vitro

Heart cells from a patient with an inherited heart disease called arrhythmogenic cardiomyopathy do not contract correctly when grown in the laboratory, researchers from Osaka University have found.


News • Multi-component procedure

SULEEI: extending the functional lives of biological heart valve prostheses

For decades now, the Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing processes and systems for cleaning, sterilization, and surface…


Article • Precision CV medicine

New biomarkers for cardiovascular disease

A range of new biomarkers and diagnostics for precision cardiovascular medicine were outlined in a session at the British Cardiovascular Society annual conference held recently in Manchester.…

Related products

Subscribe to Newsletter